Healthcare Industry News: Zevalin
News Release - January 27, 2012
Spectrum Pharmaceuticals Strengthens Commercial OperationsSpectrum Expects Fourth Quarter 2011 Revenues to Be Equal to or Greater Than Third Quarter 2011;
The Company Anticipates Filing Two New Drug Applications (NDAs) in 2012;
In Preparation of Potential Launch of Apaziquone and Belinostat in 2013, and to Bolster Worldwide Zevalin Sales, Spectrum Strengthens Commercial Team.
HENDERSON, Nev.--(Healthcare Sales & Marketing Network)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI ), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the promotions of Rick Gonzalez to Senior Vice President, Commercial; Andrew W. Amstrup to the position of Vice President, Sales, and Glenn Ravelo to Vice President, Business Solutions.
“The promotions are intended to reward our commercial team for its successes in 2011 and are also crucial as we ramp up our commercial efforts for the future,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We expect to continue to grow sales for our two marketed drugs, FUSILEV® for advanced metastatic colorectal cancer, and Zevalin® for indolent non-Hodgkin’s lymphoma. We currently expect our fourth quarter 2011 revenues to be equal to or greater than our third quarter 2011 revenues.”
Rick Gonzalez joined Spectrum in March 2008 and has had increasing responsibilities leading teams within Spectrum’s Commercial group. In his new position of Senior Vice President, Commercial, Mr. Gonzalez will be responsible for designing and leading all commercial strategies for marketed and late-stage products, including Sales, Commercial Operations, Business Solutions and Brand Management. His immediate focus is on the optimization of all resources within the commercial operation to ensure a successful launch of the Zevalin (ibritumomab tiuxetan) repositioning campaign and continued revenue growth from FUSILEV (levoleucovorin). Mr. Gonzalez will report directly to Jim Shields. Prior to joining Spectrum, Mr. Gonzalez was a founding member of the Abraxis Oncology commercial team, where he held positions in sales management, marketing and account management. Mr. Gonzalez has 20 years of experience in the pharmaceutical industry of which 14 have been in specialty markets, including Hematology/Oncology. Prior companies include GlaxoSmithKline, Roche Laboratories, Ligand Pharmaceuticals and Genzyme. Mr. Gonzalez earned his Bachelor of Science in Business Logistics from Penn State University.
Andrew Amstrup joined Spectrum in 2011, serving most recently as National Director of Sales for Zevalin. In his new position of Vice President, Sales, Mr. Amstrup will report to Mr. Gonzalez and will be responsible for the Company’s Academic and Specialty Hematology Zevalin sales teams. Mr. Amstrup has more than 30 years of pharmaceutical sales and sales management experience. Prior to joining Spectrum, he was Director of Sales for TEVA Pharmaceuticals, where he managed seven sales districts including 72 field representatives and managers. Mr. Amstrup previously spent 20 years with Bayer Corporation, most recently as Specialty Director of Sales in the Academic and Institutional Environment. Early in his career, he was Division Manager with Stuart Pharmaceuticals (now AstraZeneca PLC). Mr. Amstrup earned his Bachelor of Arts from California State University.
Glenn Ravelo has more than 25 years of pharmaceutical experience, including 21 in the oncology space. Mr. Ravelo is a seasoned professional with extensive experience in sales, sales management and account management. In his new role as Vice President of Business Solutions, Mr. Ravelo will be responsible overseeing the FUSILEV Specialty Sales Team. In addition, his responsibilities will include: Account Management, Managed Markets, Government Affairs, Logistics and Business Informatics. He will report to Mr. Gonzalez. Prior to joining Spectrum in 2007, he held various positions of increasing responsibility at Abraxis Oncology. Mr. Ravelo was a charter member of Amgen Corporation where he spent 18 years and gained experience in many areas of the business. Previously, he worked at Roche Laboratories. Mr. Ravelo earned his Bachelor of Science from Springhill College and his Master of Business Administration from Nova Southeastern.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two oncology drugs, FUSILEV® (levoleucovorin) for Injection and Zevalin®(ibritumomab tiuxetan) Injection for intravenous use. In addition, Spectrum has two drugs, apaziquone and belinostat, in late stage development with a goal of filing New Drug Applications (NDAs) with the U.S. Food & Drug Administration in 2012. The Company also has a diversified pipeline of novel drug candidates. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial drug products. The Company has aggressive business development and commercial operation teams that support a robust drug development program encompassing clinical development, medical research, regulatory affairs, biostatistics and data management. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.
Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new applications to the FDA may not receive approval, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, Zevalin®, and FUSILEV® are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
Source: Spectrum Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.